Medicare enrollees are paying far more than their prescription-drug plans for dozens of drugs covered under Medicare Part D, according to a new study from the U.S. Government Accountability Office.
For 79 drugs studied by the GAO, Medicare patients’ 2021 spending totaled $21 billion — roughly quadruple the amount that Part D plans spent on those drugs, after accounting for “rebates,” or discounts that drugmakers often pay to Part D plan sponsors or the prescription-drug middlemen known as pharmacy-benefit managers.
Comments